The pharmaceutical Anglo-Swedish AstraZeneca reported this Friday that his Vaxzevria vaccine is, after a dose, “highly effective” in preventing severe cases of covid and hospitalizations caused by the beta and delta variants of the coronavirus.
The study, developed in Canada with 69 thousand 533 infected with SARS-CoV-2 between December 2020 and May 2021, he indicated that the preparation is 82% effective, after a puncture, in the face of “hospitalization or death” caused by beta / gamma variant, first identified in South Africa (B.1.351).
Likewise, it reaches 87% efficiency against “hospitalization or death” caused by the delta variant (B.617.2, also known as “Indian”), and 90% against alpha (B.1.1.7 or “Kent”, in reference to the English county where it was first detected).
Of the total number of individuals analyzed for this study by the Canadian Immunization Research Network (CIRN), 40,828 (9.7%) were positive for some of the variants considered “worrisome”, while 28,705 (6.8%) were infected by others variants of the coronavirus.
The analysis notes that there has not been enough time yet to report on the effectiveness of Vaxzevria after the second dose, although “other studies have shown an increase in efficacy” after the second puncture.
Read also Vaccinated with the two doses of Sputnik V do not transmit Covid-19, Russian researcher
“The effectiveness of Vaxzevria after a dose against hospitalization or death was similar to that of other vaccines tested in the study, “he noted. AstraZeneca it’s a statement.
The executive vice president of R&D of the Anglo-Swedish company, Mene Pangalos, stressed that this preparation, analyzed with “real world data”, offers “a high level of protection” against the “most serious forms” of the Covid-19, even after “a single dose”.
“It is essential that we continue to protect as many people as possible in all corners of the world to be able to anticipate this deadly virus,” he added.
Read also Coronavirus in Mexico: the peoples who refuse to be vaccinated against Covid-19
NGO
– .
